Publication: Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19.
No Thumbnail Available
Identifiers
Date
2021-05-04
Authors
Ramos-Rincon, Jose Manuel
Perez-Belmonte, Luis M
Carrasco-Sanchez, Francisco Javier
Jansen-Chaparro, Sergio
De-Sousa-Baena, Mercedes
Bueno-Fonseca, Jose
Perez-Aguilar, Maria
Arevalo-Cañas, Coral
Bacete-Cebrian, Marta
Mendez-Bailon, Manuel
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Oxford University Press
Abstract
The effects of cardiometabolic drugs on the prognosis of diabetic patients with COVID-19, especially very old patients, are not well known. This work was aimed to analyze the association between preadmission cardiometabolic therapy (antidiabetic, antiaggregant, antihypertensive, and lipid-lowering drugs) and in-hospital mortality among patients ≥80 years with type 2 diabetes mellitus (T2DM) hospitalized for COVID-19. We conducted a nationwide, multicenter, observational study in patients ≥80 years with T2DM hospitalized for COVID-19 between March 1 and May 29, 2020. The primary outcome measure was in-hospital mortality. A multivariate logistic regression analysis was performed to assess the association between preadmission cardiometabolic therapy and in-hospital mortality. Of the 2 763 patients ≥80 years old hospitalized due to COVID-19, 790 (28.6%) had T2DM. Of these patients, 385 (48.7%) died during admission. On the multivariate analysis, the use of dipeptidyl peptidase-4 inhibitors (adjusted odds ratio [AOR] 0.502, 95% confidence interval [CI]: 0.309-0.815, p = .005) and angiotensin receptor blockers (AOR 0.454, 95% CI: 0.274-0.759, p = .003) were independent protectors against in-hospital mortality, whereas the use of acetylsalicylic acid was associated with higher in-hospital mortality (AOR 1.761, 95% CI: 1.092-2.842, p = .020). Other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins showed neutral association with in-hospital mortality. We found important differences between cardiometabolic drugs and in-hospital mortality in older patients with T2DM hospitalized for COVID-19. Preadmission treatment with dipeptidyl peptidase-4 inhibitors and angiotensin receptor blockers could reduce in-hospital mortality; other antidiabetic drugs, angiotensin-converting enzyme inhibitors, and statins seem to have a neutral effect; and acetylsalicylic acid could be associated with excess mortality.
Description
MeSH Terms
Aged, 80 and over
Angiotensin Receptor Antagonists
COVID-19
Cardiovascular Diseases
Diabetes Mellitus, Type 2
Dipeptidyl-Peptidase IV Inhibitors
Female
Hospital Mortality
Hospitalization
Humans
Hypoglycemic Agents
Male
SARS-CoV-2
Angiotensin Receptor Antagonists
COVID-19
Cardiovascular Diseases
Diabetes Mellitus, Type 2
Dipeptidyl-Peptidase IV Inhibitors
Female
Hospital Mortality
Hospitalization
Humans
Hypoglycemic Agents
Male
SARS-CoV-2
DeCS Terms
Mortalidad Hospitalaria
Hipoglucemiantes
Aspirina
Inhibidores de la Enzima Convertidora de Angiotensina
Inhibidores de Hidroximetilglutaril-CoA Reductasas
Antagonistas de Receptores de Angiotensina
Hipoglucemiantes
Aspirina
Inhibidores de la Enzima Convertidora de Angiotensina
Inhibidores de Hidroximetilglutaril-CoA Reductasas
Antagonistas de Receptores de Angiotensina
CIE Terms
Keywords
Age ≥ 80, Cardiometabolic therapy, Coronavirus disease-2019, Mortality, Type 2 diabetes, Área Sanitaria Norte de Córdoba
Citation
Ramos-Rincón JM, Pérez-Belmonte LM, Carrasco-Sánchez FJ, Jansen-Chaparro S, De-Sousa-Baena M, Bueno-Fonseca J, et al. Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19. J Gerontol A Biol Sci Med Sci. 2021 Jul 13;76(8):e102-e109